Search bioRxiv⌕ Search

Biology subjects

Cheruiyot, A.

Publications and source records attributed to Cheruiyot, A..

3 recordsLinked to original sources

Sustained hyperglycemia specifically targets translation of mRNAs for insulin secretion

Pancreatic {beta}-cells are specialized for coupling glucose metabolism to insulin peptide production and secretion. Acute glucose exposure robustly and coordinately increases translation of proinsulin and proteins required for secretion of mature insulin peptide. By contrast, chronically elevated glucose levels that occur during diabetes impair {beta}-cell insulin secretion and have been shown experimentally to suppress insulin translation. Whether translation of other genes critical for insulin secretion are similarly downregulated by chronic high glucose is unknown. Here, we used high-throughput ribosome profiling and nascent proteomics in MIN6 insulinoma cells to elucidate the genome-wide impact of sustained high glucose on {beta}-cell mRNA translation. Prior to induction of ER stress or suppression of global translation, sustained high glucose suppressed glucose-stimulated insulin secretion and downregulated translation of not only insulin, but also of mRNAs related to insulin secretory granule formation, exocytosis, and metabolism-coupled insulin secretion. Translation of these mRNAs was also downregulated in primary rat and human islets following ex-vivo incubation with sustained high glucose and in an in vivo model of chronic mild hyperglycemia. Furthermore, translational downregulation decreased cellular abundance of these proteins. Our findings uncover a translational regulatory circuit during {beta}-cell glucose toxicity that impairs expression of proteins with critical roles in {beta}-cell function.

cell biology↗

Nonsense Mediated RNA Decay Is a Unique Vulnerability of Cancer Cells with SF3B1 and U2AF1 Mutations

Nonsense-mediated RNA decay (NMD) is well recognized as an RNA surveillance pathway that targets aberrant mRNAs with premature translation termination codons (PTCs) for degradation; however, its molecular mechanisms and roles in health and disease remain incompletely understood. In this study, we developed a novel reporter system that can accurately measure NMD activity in individual cells. By carrying out a genome-wide CRISPR/Cas9 knockout screen using this reporter system, we identified novel NMD-promoting factors, including multiple components of the SF3B complex and other U2 spliceosome factors. Interestingly, we also found that cells with mutations in the U2 spliceosome genes SF3B1 and U2AF1--which are commonly found in myelodysplastic syndrome (MDS) and cancers--have overall attenuated NMD activity. Furthermore, we found that compared to wild type cells, SF3B1 and U2AF1 mutant cells are more sensitive to NMD inhibition, a phenotype that is accompanied by elevated DNA replication obstruction, DNA damage and chromosomal instability. Remarkably, the sensitivity of spliceosome mutant cells to NMD inhibition could be rescued by overexpression of RNase H1, which removes R-loops in the genome. Together, our findings shed new light on the functional interplay between NMD and RNA splicing and suggest a novel strategy for the treatment of MDS and cancers with spliceosome mutations.

cell biology↗

Evidence of interaction between humoral immunity and drug half-life in determining treatment outcome for artemisinin combination therapy in high transmission settings in western Kenya

The role of humoral immunity on the efficacy of artemisinin combination therapy (ACT) has not been investigated, yet naturally acquired immunity is key determinant of antimalarial therapeutic response. We conducted a therapeutic efficacy study in high transmission settings of western Kenya, which showed artesunate-mefloquine (ASMQ) and dihydroartemisinin-piperaquine (DP) were more efficacious than artemether-lumefantrine (AL). To investigate the underlying prophylactic mechanism, we compared a broad range of humoral immune responses in cohort I study participants treated with ASMQ or AL, and applied machine-learning (ML) models using immunoprofile data to analyze individual participants treatment outcome. We showed ML models could predict treatment outcome for ASMQ but no AL with high (72-92%) accuracy. Simulated PK profiling provided evidence demonstrating specific humoral immunity confers protection in the presence of sub-therapeutic residual mefloquine concentration. We concluded patient humoral immunity and partner drug interact to provide long prophylactic effect of ASMQ.

bioinformatics↗